Search

Your search keyword '"Vidaza (Medication)"' showing total 376 results
Start Over Descriptor "Vidaza (Medication)"
376 results on '"Vidaza (Medication)"'

1. FDA APPROVES AZACITIDINE FOR NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA

Subjects
United States. Food and Drug Administration, Celgene Corp., Antineoplastic agents, Leukemia, Hematopoietic stem cells -- Transplantation, Children -- Health aspects, Drug approval, Pharmaceutical industry, Antimitotic agents, News, opinion and commentary, Vidaza (Medication)
Abstract

SILVER SPRING, MD -- The following information was released by the U.S. Food and Drug Administration (FDA): On May 20, 2022, the Food and Drug Administration approved azacitidine (Vidaza, Celgene [...]

Published
2022

2. ASH: Servier's Tibsovo triumph in leukemia study primes med for combo use--and possibly Europe

Author

Kansteiner, Fraiser

Subjects
Oncology, Experimental, Drug approval, Chemotherapy, Cancer -- Chemotherapy -- Research, Pharmaceuticals and cosmetics industries, Tibsovo (Medication), Vidaza (Medication)
Abstract

Byline: Fraiser Kansteiner With a trial win in certain acute myeloid leukemia (AML) patients, Servier's cancer med Tibsovo is primed to break into front-line use as a combo treatment for [...]

Published
2021

3. United States : ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza and Venclexta in Relapsed|Refractory Acute Myeloid Leukemia at ASH

Subjects
ImmunoGen Inc., Biological products, Diseases -- Relapse, Antigens, Pharmaceutical industry, Business, international, Vidaza (Medication), Venclexta (Medication)
Abstract

ImmunoGen Inc. a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety and efficacy findings from its Phase 1b/2 study of [...]

Published
2021

4. At ASH, ImmunoGen will present preliminary data on IMGN632 in combination with Vidaza(r) and Venclexta(r) in patients with relapsed|refractory acute myeloid leukaemia

Subjects
ImmunoGen Inc., Biological products, Diseases -- Relapse, Antigens, Pharmaceutical industry, General interest, News, opinion and commentary, Vidaza (Medication), Venclexta (Medication)
Abstract

WALTHAM: ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced initial safety and efficacy findings from its Phase 1b/2 study of [...]

Published
2021

5. ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza[R] and Venclexta[R] in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Subjects
ImmunoGen Inc., Biological products, Antigens, Pharmaceutical industry, Business, Business, international, Vidaza (Medication), Venclexta (Medication)
Abstract

Triplet Demonstrated Manageable Safety Profile and Encouraging Activity, with 55% Objective Response Rate Across All Doses/Schedules in Escalation Data for IMGN632 in Frontline BPDCN Patients Will Also be Presented WALTHAM, [...]

Published
2021

6. BeiGene: China's SMIA includes VIDAZA on national reimbursement drug list

Subjects
Drug approval, Business, News, opinion and commentary, Vidaza (Medication)
Abstract

BeiGene (BGNE) announced that China's State Medical Insurance Administration has included VIDAZA on its national reimbursement drug list. VIDAZA is a nucleoside metabolic inhibitor and was approved in China for [...]

Published
2018

8. BeiGene's Vidaza now commercially available in China

Subjects
Business, News, opinion and commentary, Vidaza (Medication)
Abstract

BeiGene (BGNE) announced the commercial availability of Vidaza in China. Vidaza is a nucleoside metabolic inhibitor and was approved in China for patients with Intermediate-2 / High-risk myelodysplastic syndrome, acute [...]

Published
2018

9. Bristol Myers Squibb's decade-old Vidaza goes oral with FDA nod in acute myeloid leukemia

Subjects
Chemotherapy, Acute myelocytic leukemia -- Care and treatment, Stem cell transplantation, Business, international, Law, Vidaza (Medication)
Abstract

Vidaza boasts a long-established place in conventional treatment for patients with acute myeloid leukemia (AML). Now, its active ingredient, azacitidine, has been spun into an oral option. The FDA greenlighted [...]

Published
2020

10. Bristol Myers Squibb's decade-old Vidaza goes oral with FDA nod in acute myeloid leukemia

Subjects
Chemotherapy, Acute myelocytic leukemia -- Care and treatment, Stem cell transplantation, Pharmaceuticals and cosmetics industries, Vidaza (Medication), Idhifa (Medication)
Abstract

Vidaza boasts a long-established place in conventional treatment for patients with acute myeloid leukemia (AML). Now, its active ingredient, azacitidine, has been spun into an oral option. The FDA greenlighted [...]

Published
2020

11. AbbVie, Roche leukemia drug successful in Phase III confirmatory study

Subjects
Venetoclax -- Product development, Cancer research, Chemotherapy, Acute myelocytic leukemia, Antineoplastic agents, Bone marrow transplantation, Myeloid leukemia, Business, international, Law, Vidaza (Medication), Venclexta (Medication)
Abstract

A cancer drug made by Chicago-based AbbVie and Swiss drugmaker Roche was successful in a Phase III confirmatory trial in an aggressive form of leukemia less than a month after [...]

Published
2020

12. BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

Subjects
Bristol-Myers Squibb Co. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Finance, Company earnings/profit, Banking, finance and accounting industries, Business, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

CAMBRIDGE, Mar 02, 2020 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for [...]

Published
2020

13. Dr. Reddy's Labs launches generic azacitidine for injection in Canadian market

Subjects
Generic drugs, Antineoplastic agents, Pharmaceuticals and cosmetics industries, Vidaza (Medication)
Abstract

Byline: Our Bureau Dr. Reddy's Laboratories has launched generic azacitidine for injection 100 mg/vial, a bioequivalent generic version of Vidaza (azacitidine for injection). This is approved by Health Canada. Vidaza [...]

Published
2017

14. Mylan Launches Generic Vidaza[R] Injection

Subjects
United States. Food and Drug Administration, Azacitidine, Physical fitness, Generic drugs, Drug approval, Health, Vidaza (Medication)
Abstract

2016 JUN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Mylan N.V. (NASDAQ, TASE: MYL) announced the U.S. launch of Azacitidine for [...]

Published
2016

15. Q3 2017 Agios Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, American Society of Hematology, Vidaza (Medication), Idhifa (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome to the Agios Third Quarter 2017 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Agios' request. I would [...]

Published
2017

16. Q1 2017 Agios Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Vidaza (Medication)
Abstract

Presentation OPERATOR: Good morning, and welcome to the Agios First Quarter 2017 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at Agios's request. I would [...]

Published
2017

17. Global Blood Cancer Drugs Market Report 2020: Focus on Rituaxan|Mabthera, Gleevac|Glivec, Revlimid, Velcade, Tasigna, Pomalyst, Vidaza, Kyprolis Adcetris

Subjects
United States. Food and Drug Administration, Amgen Inc., Eli Lilly and Co., Biotechnology industries -- International economic relations, Marketing, Nilotinib, Pharmaceutical industry -- International economic relations, Antineoplastic agents, Brentuximab vedotin, Drugs, Pomalidomide, Carfilzomib, General interest, News, opinion and commentary, MabThera (Medication), Revlimid (Medication), Vidaza (Medication), Adcetris (Medication), Tasigna (Medication), Velcade (Medication)
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Blood Cancer Drugs Global Market Report 2020' report has been added to ResearchAndMarkets.com's offering. The global blood cancer drugs [...]

Published
2019

18. Global Blood Cancer Drugs Market Report 2020: Focus on Rituaxan/Mabthera, Gleevac/Glivec, Revlimid, Velcade, Tasigna, Pomalyst, Vidaza, Kyprolis Adcetris

Subjects
United States. Food and Drug Administration, Amgen Inc., Eli Lilly and Co., Biotechnology industries -- International economic relations, Marketing, Nilotinib, Pharmaceutical industry -- International economic relations, Antineoplastic agents, Brentuximab vedotin, Drugs, Pomalidomide, Carfilzomib, Business, Business, international, MabThera (Medication), Revlimid (Medication), Vidaza (Medication), Adcetris (Medication), Tasigna (Medication), Velcade (Medication)
Abstract

M2 PRESSWIRE-December 11, 2019-: Global Blood Cancer Drugs Market Report 2020: Focus on Rituaxan/Mabthera, Gleevac/Glivec, Revlimid, Velcade, Tasigna, Pomalyst, Vidaza, Kyprolis Adcetris (C)1994-2019 M2 COMMUNICATIONS RDATE:11122019 The 'Blood Cancer Drugs [...]

Published
2019

19. Global Blood Cancer Drugs Market Report 2020: Focus on Rituaxan/Mabthera, Gleevac/Glivec, Revlimid, Velcade, Tasigna, Pomalyst, Vidaza, Kyprolis Adcetris - ResearchAndMarkets.com

Subjects
United States. Food and Drug Administration, Amgen Inc., Eli Lilly and Co., Biotechnology industries -- International economic relations, Marketing, Nilotinib, Pharmaceutical industry -- International economic relations, Antineoplastic agents, Brentuximab vedotin, Drugs, Pomalidomide, Carfilzomib, Business, Business, international, MabThera (Medication), Revlimid (Medication), Vidaza (Medication), Adcetris (Medication), Tasigna (Medication), Velcade (Medication)
Abstract

DUBLIN -- The 'Blood Cancer Drugs Global Market Report 2020' report has been added to ResearchAndMarkets.com's offering. The global blood cancer drugs market was valued at about $33 billion in [...]

Published
2019

20. BeiGene Reports Second Quarter 2019 Financial Results

Subjects
Bristol-Myers Squibb Co. -- Company sales and earnings -- Officials and employees, Stock Exchange of Hong Kong Ltd. -- Company sales and earnings -- Officials and employees, Securities industry -- International economic relations -- Company sales and earnings -- Officials and employees, Securities industry, Company earnings/profit, Banking, finance and accounting industries, Business, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

CAMBRIDGE, Mass. and BEIJING, China, Aug 08, 2019 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted [...]

Published
2019

21. Myelodysplastic Syndrome Treatment Market Scenario With Impact Of Drivers And Challenges 2025

Subjects
Celgene Corp. -- Forecasts and trends, Motor vehicle drivers, Pharmaceutical industry -- Forecasts and trends, Deferasirox, Decitabine, Explosions, Genes, Gene mutation, Market trend/market analysis, General interest, News, opinion and commentary, Vidaza (Medication)
Abstract

SEATTLE: Coherent Market Insights has issued the following news release: Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature [...]

Published
2019

22. BeiGene Reports First Quarter 2019 Financial Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Abraxane (Medication), Revlimid (Medication), Vidaza (Medication)
Abstract

CAMBRIDGE, May 09, 2019 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for [...]

Published
2019

23. Lupin receives FDA approval for generic version Vidaza(R)

Subjects
United States. Food and Drug Administration, Celgene Corp., Pharmaceutical industry, Drug approval, Anemia -- Drug therapy, Generic drugs, Azacitidine, Leukemia, Thrombocytopenia, Neutropenia, Explosions, Biotechnology industry, Vidaza (Medication)
Abstract

It is a generic version of Celgene Corporation's Vidaza(R) Pharma major Lupin announced that it has received approval for its Azacitidine for Injection, 100 mg Single-Dose Vial from the United [...]

Published
2019

24. Lupin receives FDA approval for Azacitidine for Injection, 100 mg Single-Dose Vial

Subjects
United States. Food and Drug Administration, Celgene Corp., Pharmaceutical industry, Vidaza (Medication)
Abstract

ENPNewswire-March 1, 2019--Lupin receives FDA approval for Azacitidine for Injection, 100 mg Single-Dose Vial (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 28022019 - Mumbai - Pharma major Lupin announced that it [...]

Published
2019

25. Lupin gets USFDA's approval for Azacitidine for Injection, 100 mg Single-Dose Vial

Subjects
United States. Food and Drug Administration, Celgene Corp., Pharmaceutical industry, Azacitidine -- Dosage and administration, Anemia, Generic drugs -- Dosage and administration, Thrombocytopenia, Antineoplastic agents, Neutropenia, Business, international, Vidaza (Medication)
Abstract

With this approval, Lupin strengthens its complex generics portfolio in Injectables Lupin has received approval for its Azacitidine for Injection, 100 mg Single-Dose Vial from the United States Food and [...]

Published
2019

26. BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

Subjects
Celgene Corp. -- Company sales and earnings -- Officials and employees, Pharmaceutical industry -- Company sales and earnings -- Officials and employees, Company earnings/profit, Banking, finance and accounting industries, Business, Abraxane (Medication), Revlimid (Medication), Vidaza (Medication)
Abstract

CAMBRIDGE, Mass. and BEIJING, China, Feb 27, 2019 (GLOBE NEWSWIRE via COMTEX) -- Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong [...]

Published
2019

28. Celgene Corp Analyst and Investor Event at American Society of Hematology (ASH) - Final

Subjects
Celgene Corp., Professional associations, Pharmaceutical industry, Business, Revlimid (Medication), Vidaza (Medication)
Abstract

Presentation UNIDENTIFIED PARTICIPANT: Let me begin by welcoming you to Celgene's ASH Investor and Analyst Event. Thank you for coming. It's a great crowd. And obviously ASH is an extremely [...]

Published
2016

29. Celgene Corp at Citi Biotech Conference - Final

Subjects
Citigroup Inc. -- Conferences, meetings and seminars, Biotechnology -- Conferences, meetings and seminars, Biotechnology industries -- Conferences, meetings and seminars, Financial services -- Conferences, meetings and seminars, Financial services industry, Business, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

Presentation ROBYN KARNAUSKAS, ANALYST, CITIGROUP: Next we have Celgene. The future of Celgene's hematology/oncology franchise, which -- I'm really lucky to have Michael Pehl with us. He's the President of [...]

Published
2016

30. BeiGene Announces National Reimbursement Inclusion of VIDAZA(r) (Azacitidine for Injection) by the State Medical Insurance Administration in China

Subjects
Azacitidine, Drug approval, Health insurance, General interest, News, opinion and commentary, Vidaza (Medication)
Abstract

CAYMAN ISLANDS: BeiGene, LTD. has issued the following press release: BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs [...]

Published
2018

31. BeiGene Announces National Reimbursement Inclusion of VIDAZA(R) (Azacitidine for Injection) by the State Medical Insurance Administration in China

Subjects
Celgene Corp., Cancer treatment, Azacitidine, Pharmaceutical industry, Health insurance, Banking, finance and accounting industries, Business, Vidaza (Medication)
Abstract

BEIJING, China and CAMBRIDGE, Mass., Oct 10, 2018 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted [...]

Published
2018

32. Panacea Biotec inks agreement with Natco Pharma, Breckenridge Pharmaceutical

Subjects
Celgene Corp., Azacitidine, Generic drugs, Pharmaceutical industry, Business, international, Vidaza (Medication)
Abstract

Azacitidine is a generic equivalent of Vidaza, which is marketed by Celgene Corporation, US Panacea Biotec has entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical Inc. for [...]

Published
2018

33. BeiGene Reports Second Quarter 2018 Financial Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

CAMBRIDGE, Mass. and BEIJING, China, Aug 09, 2018 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted [...]

Published
2018

35. BeiGene Announces Commercial Availability of VIDAZA(r) (Azacitidine for Injection) in China

Subjects
Celgene Corp., Azacitidine, Pharmaceutical industry, General interest, News, opinion and commentary, Vidaza (Medication)
Abstract

Cayman Islands: BeiGene, Ltd. has issued the following press release: BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the [...]

Published
2018

36. BeiGene Announces Commercial Availability of VIDAZA(r) (Azacitidine for Injection) in China

Subjects
Celgene Corp., Azacitidine, Pharmaceutical industry, General interest, News, opinion and commentary, Vidaza (Medication)
Abstract

Beijing , China: BeiGene has issued the following press release: BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the [...]

Published
2018

37. BeiGene Announces Commercial Availability of VIDAZA(R) (Azacitidine for Injection) in China

Subjects
Celgene Corp., Cancer treatment, Azacitidine, Pharmaceutical industry, Banking, finance and accounting industries, Business, Vidaza (Medication)
Abstract

BEIJING, China, and CAMBRIDGE, Mass., Feb 05, 2018 (GLOBE NEWSWIRE via COMTEX) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology [...]

Published
2018

38. Global Blood Cancer Drugs Market Report 2020: Focus on Rituaxan/Mabthera, Gleevac/Glivec, Revlimid, Velcade, Tasigna, Pomalyst, Vidaza, Kyprolis Adcetris - ResearchAndMarkets.com

Subjects
United States. Food and Drug Administration, Amgen Inc., Eli Lilly and Co., Biotechnology industries -- International economic relations, Marketing, Nilotinib, Pharmaceutical industry -- International economic relations, Antineoplastic agents, Brentuximab vedotin, Drugs, Immunotherapy, Pomalidomide, Editors, Carfilzomib, Health, MabThera (Medication), Revlimid (Medication), Vidaza (Medication), Adcetris (Medication), Tasigna (Medication), Velcade (Medication)
Abstract

2019 DEC 25 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- The 'Blood Cancer Drugs Global Market Report 2020' report has been added to ResearchAndMarkets.com's offering. [...]

Published
2019

39. Agios Pharmaceuticals Inc Research and Development (R&D) Day - Final

Subjects
Industrial research, Research and development, Business, Vidaza (Medication)
Abstract

Presentation DAVID SCHENKEIN, CEO, AGIOS PHARMACEUTICALS INC.: All right. Good morning, everybody. I'm David Schenkein, I really appreciate that everybody's come here to spend some time with us this morning. [...]

Published
2015

41. Celgene Corp Financial Reports: Celgene Reports Record First Quarter 2010 Operating and Financial Results

Subjects
Pharmion Corp. -- Company sales and earnings, Celgene Corp. -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Thalomid (Medication)
Abstract

New Jersey: Celgene Corp has issued the following First Quarter 2010: Celgene Corporation (NASDAQ: CELG): 2010 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 31 Percent to $789 Million; [...]

Published
2017

42. Celgene Corp Financial Reports: Celgene Reports Third Quarter 2015 Operating and Financial Results

Subjects
Celgene Corp. -- Officials and employees, Pharmaceutical industry -- Officials and employees, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication), Otezla (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Third Quarter 2015: Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,313 million for the third quarter of 2015, an 18 percent [...]

Published
2017

43. Celgene Corp Financial Reports: Celgene Reports Record Second Quarter 2010 Operating and Financial Results

Subjects
Pharmion Corp. -- Company sales and earnings -- Officials and employees, Celgene Corp. -- Company sales and earnings -- Officials and employees, Biotechnology industries -- Company sales and earnings -- Officials and employees, Pharmaceutical industry -- Company sales and earnings -- Officials and employees, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Thalomid (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Second Quarter 2010: 2010 Second Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAAP Total Revenue $853 [...]

Published
2017

44. Celgene Corp Financial Reports: Celgene Reports Record Third Quarter 2010 Operating and Financial Results

Subjects
EntreMed Inc. -- Company sales and earnings, Pharmion Corp. -- Company sales and earnings, Celgene Corp. -- Company sales and earnings, Health care industry -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Health care industry, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Thalomid (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Third Quarter 2010: 2010 Third Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 31 Percent to $908 Million; GAAP Total Revenue $910 [...]

Published
2017

45. Celgene Corp Financial Reports: Celgene Reports Record Non-GAAP Fourth Quarter and Full Year 2010 Operating and Financial Results

Subjects
Pharmion Corp., Celgene Corp., Biotechnology industries, Pharmaceutical industry, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Thalomid (Medication), Abraxane (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Fourth Quarter: Global REVLIMID(r) Net Product Sales Increased 42 Percent to $708 Million Global VIDAZA(r) Net Product Sales Increased 20 Percent to [...]

Published
2017

46. Celgene Corp Financial Reports: Celgene Reports Record Second Quarter 2011 Operating and Financial Results

Subjects
Pharmion Corp. -- Company sales and earnings, Celgene Corp. -- Company sales and earnings, Biotechnology industries -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Second Quarter 2011: SUMMIT, N.J., Jul 28, 2011 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG): 2011 Second Quarter Financial Results Year-Over-Year Non-GAAP [...]

Published
2017

47. Celgene Corp Financial Reports:m Celgene Reports Record First Quarter 2011 Operating and Financial Results

Subjects
Celgene Corp. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, Revlimid (Medication), Vidaza (Medication), Istodax (Medication), Abraxane (Medication)
Abstract

New Jersey: Celgene Corp has issued the following First Quarter 2011: 2011 First Quarter Financial Results Year-Over-Year Non-GAAP Total Revenue Increased 40 Percent to $1.11 Billion; GAAP Total Revenue $1.13 [...]

Published
2017

48. Celgene Corp Financial Reports: Celgene Reports Strong Fourth Quarter and Full Year 2012 Operating and Financial Results

Subjects
Celgene Corp. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, General interest, News, opinion and commentary, American Society of Hematology, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Fourth Quarter:. Celgene Corporation (NASDAQ: CELG) reported net product sales of $1,416 million for the fourth quarter 2012, a 14 percent increase [...]

Published
2017

49. Celgene Corp Financial Reports: Celgene Reports Fourth Quarter and Full Year 2014 Operating and Financial Results

Subjects
Celgene Corp., Pharmaceutical industry, General interest, News, opinion and commentary, American Society of Hematology, Revlimid (Medication), Vidaza (Medication), Abraxane (Medication), Otezla (Medication)
Abstract

New Jersey: Celgene Corp has issued the following Fourth Quarter : - Celgene Corporation (NASDAQ:CELG) reported operating results for the fourth quarter and full year of 2014. For the fourth [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results